AmCham’s Pharmaceutical Committee has suggestions. Year after year, a key concern of the major pharmaceutical companies operating in Taiwan is the ease with which new drugs and new indications (meaning new applications for existing treatments) can enter the market. Given Taiwan’s single-payer universal healthcare system, much depends on whether the National Health Insurance Administration (NHIA)…

Should the current target-expenditure system be extended? When the Taiwan government five years ago was working on how to revamp the National Health Insurance (NHI) program to help ensure its long-term sustainability, one of the new measures it adopted was a suggestion from the pharmaceutical industry that had been broached in AmCham Taipei’s 2010 Taiwan…

A visiting delegation urges early passage of Patent Linkage legislation. During a recent visit to Taipei, a six-member delegation from the Washington, DC-based Pharmaceutical Research and Manufacturers of America (PhRMA) urged Taiwan’s legislature to give early attention to pending bills to strengthen intellectual property protection for pharmaceuticals. Passage of the proposed amendments to the Pharmaceutical…